CClinicalTrials.gg
RecruitingNCT06193161Updated Apr 9, 2025

Prolonged Exposure for Swedish Immigrants

An interventional study of Therapist-supported internet delivered prolonged exposure in Posttraumatic Stress Disorder, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare therapist-guided internet delivered prolonged exposure (I-PE) in simple english to a waiting list condition for immigrants in Sweden diagnosed with post-traumatic stress disorder (PTSD).

The main objectives are to establish feasibility and preliminary efficacy of I-PE for immigrants with PTSD in a single-blind, parallel-group superiority Randomized Controlled Trial (N=100) comparing I-PE with a waiting-list condition, starting with a nested pilot (N=30) to ensure feasible and acceptable recruitment and treatment strategies. Study participants will be randomly assigned to either eight weeks of I-PE or a waiting-list for the same amount of time on a 1:1 ratio without restriction. Feasibility and acceptability data will be reported including recruitment rate, sample demographics, data attrition, treatment adherence and a detailed dropout analysis. A preliminary investigation of the within-group effect size will also be conducted. Recruitment is designed to be broadly inclusive with minimal exclusion criteria.

Read the detailed description

There is an urgent need for dissemination of evidence-based treatments for PTSD beyond the Swedish language criteria and developed in an easy-to-read manner and develop the treatment so that it can be easily made available to a large number of afflicted who are excluded from treatment.The overall aim of the study is to evaluate I-PE for immigrants with PTSD living in Sweden who can read and write easy English. The treatment will be written in easy English and adapted to the target population with regards to specific contextual characteristics.

The study is a single-blind, parallel-group superiority randomized controlled trial with 100 participants that will compare I-PE with a waiting list condition. The primary outcome is the self-rated Posttraumatic Stress Disorder Checklist version 5 (PCL-5) at the 1-month follow up. Secondary outcomes are the blind-rater administered Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), self-rated symptoms of depression quality of life, dropout rate, level of health care utilization, satisfaction with treatment and negative effects. Patients in the control arm will be crossed over to I-PE treatment after completion of the 1 month follow up (primary endpoint). Assessments will be conducted pre-treatment, post-treatment, 1 month (primary endpoint) and 6 months after treatment.

02

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • PTSD
  • digital treatment
  • therapist-guided treatment
  • migrants
  • prolonged exposure
03

In context

Stress Disorders, Post-Traumatic

2,239 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 554 are open to participants now.

This study's planned enrollment of 100 is above the median of 70 across 1,858 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current primary diagnosis of PTSD, according to the diagnostic criteria based on Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5; American Psychiatric Association, 2013)
  • ≥ 18 years
  • Able to read and write in English
  • Immigrant residing in Sweden
  • Able to provide digital informed consent
  • Daily access to a computer or device with internet connection

Exclusion criteria

Exclusion Criteria:

  • PTSD is not the primary treatment concern
  • Initiation or adjustment of any psychotropic medication within the last 4 weeks prior to commencement of treatment
  • Serious mental health symptoms, such as mania, psychosis, alcohol, or substance use disorders or current suicide risk warranting immediate clinical attention.
  • Ongoing trauma-focused CBT or Eye movement desensitization and reprocessing therapy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Therapist-guided internet delivered prolonged exposure

    Therapist-supported internet delivered prolonged exposure comprising psychoeducation about PTSD, controlled breathing, imaginal exposure including processing, in vivo exposure and relapse prevention. The treatment will be delivered in a digital platform for eight weeks. Participants will have access to a therapist that will guide them through treatment in a text based format.

    Behavioral: Therapist-supported internet delivered prolonged exposure

  • No intervention
    Waiting list

    Waiting list up for eight weeks and up until the 1-month follow up.

Interventions

  • BehavioralTherapist-supported internet delivered prolonged exposure

    Therapist-supported internet delivered prolonged exposure for eight weeks.

06

What researchers measure

Primary outcomes

  1. Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-report measure based upon the Diagnostic and Statistical Manual (DSM-5) criteria for PTSD. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.

    Time frame: Baseline, through the treatment period up to eight weeks, and 1-month and 6-month after treatment completion.

Secondary outcomes

  1. Change in PTSD symptoms as assessed by the Clinician Administered PTSD Scale (CAPS-5)

    The CAPS-5 is structured interview that assesses the Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) criteria for PTSD (Weathers et al., 2013). Each item is rated on a severity scale ranging from 0 (Absent) to 4 (Extreme/incapacitating) and combines information about frequency and intensity for each of the 20 symptoms. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.

    Time frame: Baseline up to 1-month after treatment completion

  2. Change in depression as assessed by The Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms. Scores are calculated based on how frequently a person experiences 9 symptoms of depression ranging from "not at all" response is scored as 0; "several days" response is 1; "more than half the days" response is 2; and "nearly every day" response is 3. Higher scores represents more depressive symptoms.

    Time frame: Baseline, immediately after treatment completion, 1-month and 6-month after treatment completion

  3. Change in general quality of life assessed by 12-Item Short-Form Health Survey (SF-12)

    The SF-12 is a health-related quality-of-life questionnaire consisting of twelve questions that measure eight health domains to assess physical and mental health. Physical health-related domains include General Health (GH), Physical Functioning (PF), Role Physical (RP), and Body Pain (BP). Scores range from 0 to 100. A higher score means higher health.

    Time frame: Baseline, immediately after treatment completion, 1-month and 6-month after treatment completion

  4. Treatment credibility assessed by the Credibility/expectancy scale (CEQ)

    Measures treatment expectancy and rationale credibility. The CEQ is a 5-item measure of the treatment's credibility and the patients' expectations. The patients assess each domain on a 11-point likert scale (scored 0-10), with a total score ranging between 0-50 where higher score indicates higher credibility and higher expectations.

    Time frame: Treatment week 3 (three weeks from baseline).

  5. Change in stigma and barriers related to mental health and competency in mental health assessed by the Stigma-9 Questionnaire (STIG-9),

    The STIG-9 consists of nine items assessing cognitive, behavioural and affective aspects of perceived mental health-related stigma. The item responses are summarized in a sum score ranged 0-27 points. Higher scores indicate stronger expectations of negative societal beliefs, feelings, and behaviours towards 'mentally ill' people.

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

  6. Change in stigma and barriers related to mental health and competency in mental health assessed Barriers to Access to Care Evaluation Scale (BACES)

    The Barriers to Access to Care Evaluation (BACE) is a 30-item measure scored from 0 (not at all) to 3 (a lot) with higher scores indicating a greater barrier.

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

  7. Change in stigma and barriers related to mental health and competency in mental health assessed Mental Health Knowledge Schedule (MHKS)

    MHKS is a twelve-item scale comprising domains of relevant evidence-based knowledge in relation to stigma toward mental illness. Items are coded on an ordinal scale (1-5). Items which the respondent strongly agrees with score 5 points; 1 point reflects a response to which the respondent strongly disagrees. The total score is calculated by adding the points obtained for each of the 12 items. Higher total scores correspond to greater knowledge

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

  8. Change in Treatment inventory of costs associated with psychiatric illness (TIC-P)

    Self-rated questionnaire on healthcare utilization and productivity losses in patients with a psychiatric disorder. The TIC-P questionnaire measures costs in two dimensions: use of health resources and loss of productivity. Lower cost is better.

    Time frame: Baseline, immediately after treatment completion and 1-month after treatment completion

  9. Treatment satisfaction measured by the Client Satisfaction Questionnaire (CSQ-8

    The CSQ-8 yields a single score measuring a single dimension of overall satisfaction. An "overall score" is calculated by summing the score on each of the eight scale item. Scores range from 8 to 32, with higher values indicating higher satisfaction.

    Time frame: Immediately after treatment completion

  10. Treatment satisfaction measured by the Internet Evaluation and Utility Questionnaire (IEUQ)

    The Internet Evaluation and Utility Questionnaire (IEUQ) is a 13-item measure that examines the participants' experiences of a web-based intervention. Score range from 0-72. Higher values indicating higher satisfaction.

    Time frame: Immediately after treatment completion

  11. Adverse events related to treatment measured by the Negative effects questionnaire-20.

    Self-rated questionnaire on negative effects. It contains 20 items that are scored on a five point Likert-scale (0-4) and differentiates between negative effects that are attributed to treatment and those possibly caused by other circumstances. The total score of the NEQ ranges from 0 to 80 points, a higher score reflects more negative effects.

    Time frame: 1-mont after treatment completion

Other outcomes

  1. Number of completed treatment modules

    Data will be gathered on total number of completed modules during the 8 week treatment.

    Time frame: Baseline up to treatment completion at 8 weeks

  2. Number of messages sent and received in the digital platform

    Data will be gathered on total number of messages sent and received back and forth between the participant and the therapist during the 8 week treatment.

    Time frame: Baseline up to treatment completion at 8 weeks

  3. Experience with the digital treatment as assessed by qualitative interviews

    During the nested study phase a subsample of the participants (N=5-15) will be interviewed at post-treatment regarded treatment comprehension, language adaptions and relevance.

    Time frame: Immediately after treatment completion

  4. The proportion of participants that conducts the weekly measures and further assessment points

    The proportion of participants that conducts the weekly measures and further assessment points

    Time frame: Baseline up to 6-month after treatment completion

  5. Number of drop-outs from treatment

    Number of drop-outs from treatment

    Time frame: Completion of the treatment period, up to 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Karolinska Institutet
    Solna, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06193161
Lead sponsor
Karolinska Institutet
Responsible party
Maria Bragesjo (Principal investigator, Clinical psychologist, PhD, Karolinska Institutet) — Principal investigator
First posted
Jan 5, 2024
Start date
Mar 15, 2024
Primary completion
Oct 15, 2025 (estimated)
Completion
Mar 15, 2026 (estimated)
Last update
Apr 9, 2025

Study contacts

Maria Bragesjö, PhD
Contact
maria.bragesjo@ki.se
+46703399387
Olof Molander, PhD
Contact
olof.molander@ki.se
Maria Bragesjö, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion